Delanzomib (CEP-18770)
| Overview | |
| Catalog # | bs-7051c-10mg-solid |
| Product Name | Delanzomib (CEP-18770) |
| Specifications | |
| Storage Buffer | Powder |
| Storage Condition | Store in dry, dark place at -20C for 1 year. |
| Target | |
| Product Information | Molecular Weight: 413.28 Formula: C21 H28 B N3 O5 CAS Number: 847499-27-8 InChi Key: SJFBTAPEPRWNKH-CCKFTAQKSA-N InChi: InChI=1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H2,1-3H3,(H,24,28)(H,25,27)/t14-,18+,19+/m1/s1 Smiles: CC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1=CC=CC(=N1)C1C=CC=CC=1)[C@@H](C)O)B(O)O Purity: 98.0 Solubility: Soluble in DMSO, not in water Appearance: Solid Power. Shelf Life: 1.0 years |
| Description | Delanzomib, also known as CEP-18770, is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. |
Powered by Bioz